ANALYSIS: How GSK’s Canada SC hearing unfolded
The Supreme Court of Canada met last week to hear the Canadian Revenue Authority’s (CRA) appeal and GlaxoSmithKline’s (GSK) response in a case to decide whether GSK paid too much for active pharmaceutical ingredients (API) from a Swiss associated enterprise.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: